Cellular mechanisms and local progenitor activation to regulate skeletal muscle mass

被引:48
作者
Cassano, Marco [1 ]
Quattrocelli, Mattia [1 ]
Crippa, Stefania [1 ]
Perini, Ilaria [1 ]
Ronzoni, Flavio [1 ,2 ]
Sampaolesi, Maurilio [1 ,2 ]
机构
[1] SCIL Katholieke Univ Leuven, B-3000 Louvain, Belgium
[2] Univ Pavia, I-27100 Pavia, Italy
关键词
Muscle hypertrophy; AKT; Magic-F1; FOXO TRANSCRIPTION FACTORS; GROWTH-FACTOR-I; DYSTROPHIN-GLYCOPROTEIN COMPLEX; SATELLITE CELL; IGF-I; STEM-CELL; MUSCULAR-DYSTROPHY; UBIQUITIN LIGASES; MDX MOUSE; MYOBLAST DIFFERENTIATION;
D O I
10.1007/s10974-010-9204-y
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Skeletal muscle hypertrophy is a result of increased load, such as functional and stretch-overload. Activation of satellite cells and proliferation, differentiation and fusion are required for hypertrophy of overloaded skeletal muscles. On the contrary, a dramatic loss of skeletal muscle mass determines atrophy settings. The epigenetic changes involved in gene regulation at DNA and chromatin level are critical for the opposing phenomena, muscle growth and atrophy. Physiological properties of skeletal muscle tissue play a fundamental role in health and disease since it is the most abundant tissue in mammals. In fact, protein synthesis and degradation are finely modulated to maintain an appropriate muscle mass. When the molecular signaling is altered muscle wasting and weakness occurred, and this happened in most common inherited and acquired disorders such as muscular dystrophies, cachexia, and age-related wasting. To date, there is no accepted treatment to improve muscle size and strength, and these conditions pose a considerable anxiety to patients as well as to public health. Several molecules, including Magic-F1, myostatin inhibitor, IGF, glucocorticoids and microRNAs are currently investigated to interfere positively in the blueprint of skeletal muscle growth and regeneration.
引用
收藏
页码:243 / 253
页数:11
相关论文
共 135 条
[11]  
Aziz MH, 2003, INT J ONCOL, V23, P17
[12]  
Bamman MM, 2001, AM J PHYSIOL-ENDOC M, V280, pE383
[13]  
Baracos VE, 2001, CANCER, V92, P1669, DOI 10.1002/1097-0142(20010915)92:6+<1669::AID-CNCR1495>3.0.CO
[14]  
2-S
[15]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[16]  
Barton-Davis ER, 1999, ACTA PHYSIOL SCAND, V167, P301
[17]   Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells [J].
Beauchamp, JR ;
Heslop, L ;
Yu, DSW ;
Tajbakhsh, S ;
Kelly, RG ;
Wernig, A ;
Buckingham, ME ;
Partridge, TA ;
Zammit, PS .
JOURNAL OF CELL BIOLOGY, 2000, 151 (06) :1221-1233
[18]   Identification of ubiquitin ligases required for skeletal muscle atrophy [J].
Bodine, SC ;
Latres, E ;
Baumhueter, S ;
Lai, VKM ;
Nunez, L ;
Clarke, BA ;
Poueymirou, WT ;
Panaro, FJ ;
Na, EQ ;
Dharmarajan, K ;
Pan, ZQ ;
Valenzuela, DM ;
DeChiara, TM ;
Stitt, TN ;
Yancopoulos, GD ;
Glass, DJ .
SCIENCE, 2001, 294 (5547) :1704-1708
[19]   Functional improvement of dystrophic muscle by myostatin blockade [J].
Bogdanovich, S ;
Krag, TOB ;
Barton, ER ;
Morris, LD ;
Whittemore, LA ;
Ahima, RS ;
Khurana, TS .
NATURE, 2002, 420 (6914) :418-421
[20]   Myostatin propeptide-mediated amelioration of dystrophic pathophysiology [J].
Bogdanovich, S ;
Perkins, KJ ;
Krag, TOB ;
Whittemore, SA ;
Khurana, TS .
FASEB JOURNAL, 2005, 19 (06) :543-549